Poly(lactide-co-glycolide) nanoparticles for peroral delivery of bioactives

Current Opinion in Colloid and Interface Science

Volumn 16, Issue 3, 2011, Pages 238-245

  Grama, C N ^a   Ankola, D D ^a   Kumar, M N V Ravi ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Antioxidants; Bioavailability; Biodegradable; Nanoparticles; Oral delivery; PLGA

Indexed keywords

ANTIOXIDANTS; BIOAVAILABILITY; BIODEGRADABLE; ORAL DELIVERY; PLGA;

BIOCHEMISTRY; FUNCTIONAL POLYMERS;

NANOPARTICLES;

AMPHOTERICIN B DEOXYCHOLATE; ATORVASTATIN; CURCUMIN; CYCLOSPORIN A; DOXORUBICIN; ELLAGIC ACID; EPIGALLOCATECHIN GALLATE; ESTRADIOL; LIPICURE; NANOPARTICLE; PACLITAXEL; POLYGLACTIN; UBIDECARENONE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; BREAST CANCER; DIABETES MELLITUS; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG TRANSPORT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAXIMUM PLASMA CONCENTRATION; METABOLIC SYNDROME X; NANOTECHNOLOGY; NEPHROTOXICITY; NONHUMAN; PARTICLE SIZE; POLYMERIZATION; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 79955978422     PISSN: 13590294     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cocis.2010.11.005     Document Type: Review

References (72)

1. Amidon G.L., Lennernas H., Shah V.P., Crison J.R. A theoretical basis for biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995, 12:413-420.
2. Lindenderg M., Kopp S., Dressman J.B. Classification of orally administered drugs on the world health organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 2004, 58:265-278.
3. Goddeeris G., Willems T., Houthoofd K., Martens J.A., Van den Mooter G. Dissolution enhancement of the anti-HIV drug UC 781 by formulation in a ternary solid dispersion with TPGS 1000 and Eudragit E100. Eur J Pharm Biopharm 2008, 70:861-868.
4. Serajuddin A.T.M. Salt formation to improve drug solubility. Adv Drug Deliv Rev 2007, 59:603-616.
5. Buur A., Yamamoto A., Lee V.H.L. Penetration of 5-fluorouracil and prodrugs across the intestine of the albino rabbit: evidence for shift in absorption site from the upper to the lower region of the gastrointestinal tract by prodrugs. J Control Release 1990, 14:43-51.
6. Li J., Loh X.J. Cyclodextrin-based supramolecular architectures: syntheses, structures, and applications for drug and gene delivery. Adv Drug Deliv Rev 2008, 60:1000-1017.
7. Sundar S. Liposomal amphotericin B. Lancet 2001, 357:801-802.
8. Panchagnula R. Pharmaceutical aspects of paclitaxel. Int J Pharm 1998, 172:1-15.
9. Helderman J.H. Lessons from the neoral global database. Transplant Proc 1998, 30:1721-1722.
10. Rauwerda H., Roos M., Hertzberger B.O., Breit T.M. The promise of a virtual lab in drug discovery. Drug Discov Today 2006, 11:228-236.
11. Hood L., Perlmutter R.M. The impact of systems approaches on biological problems in drug discovery. Nat Biotechnol 2004, 22:1215-1217.
12. Lipinski C. Poor aqueous solubility problem: an industry wide problem in drug discovery. Am Pharm Rev 2002, 5:82-85.
13. Tan M.L., Choong P.F.M., Dass C.R. Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery. Peptides 2010, 31:184-193.
14. Langer R. New methods for drug delivery. Science 1990, 249:1527-1533.
15. Langer R. Drugs on target. Science 2001, 293:58-59.
16. Kopecek J. Smart and genetically engineered biomaterials and drug delivery systems. Eur J Pharm Sci 2003, 20:1-16.
17. Chen H., Langer R. Oral particulate delivery: status and future trends. Adv Drug Deliv Rev 1998, 34:339-350.
18. Speiser P., Kreuter J. In vitro studies of poly(metylmethacrylate) adjuvants. J Pharm Sci 1976, 65:1624-1627.
19. Gref R., Minamitake Y., Peracchia M.T., Trubetskoy V., Trochilin V., Langer R. Biodegradable long-circulating polymeric nanospheres. Science 1994, 263:1600-1603.
20. Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 2003, 55:329-347.
21. Murphy E.A., Majeti B.K., Barnes L.A., Makale M., Weis S.M., Lutu-Faga K., et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA 2008, 105:9343-9348.
22. Park S.J., Taton T.A., Mirkin C.A. Array-based electrical detection of DNA with nanoparticle probes. Science 2002, 295:1503-1506.
23. Thamake S.I., Ranjan A., Raut S.L., Gryczynski Z., Vishwanatha J.K. Formulation and characterization of antibody coated Poly(lactic-co-glycolic acid) nanoparticles to target metastatic cancer. FASEB J 2010, 520:8.
24. Dhar S., Gu F.X., Langer R., Farokhzad O.C., Lippard S.J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA 2008, 105:17356-17361.
25. Yezhelyev M.V., Gao X., Xing Y., Al-Hajj A., Nie S., O'Regan R.M. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol 2006, 7:657-667.
26. Mitragotri S. In drug delivery, shape does matter. Pharm Res 2009, 26:232-234.
27. Champion J.A., Katare Y.K., Mitragotri S. Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J Control Release 2007, 12:3-9.
28. Gratton S.E.A., Ropp P.A., Pohlhaus P.D., Luft L.C., Madden V.J., Napier M.E., DeSimone J.M. The effect of particle design on cellular internalization pathways. Proc Nat Acad Sci 2008, 105:11613-11618.
29. Bhabra G., Sood A., Fisher B., Cartwright L., Saunders M., Evans W.H., et al. Nanoparticles can cause DNA damage across a cellular barrier. Nat Nanotechnol 2009, 4:876-883.
30. Nel A., Xia T., Madler L., Li N. Toxic potential of materials at the nanolevel. Science 2006, 311:622-627.
31. Kreuter J., Ramge P., Petrov V., Hamm S., Gelperina S.E., Engelhardt B., et al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 2003, 20:409-416.
32. Bhardwaj V., Hariharan S., Bala I., Lamprecht A., Kumar N., Panchagnula R., et al. Pharmaceutical aspects of polymeric nanoparticles for oral delivery. J Biomed Nanotechnol 2005, 1:235-258.
33. Jung T., Kamm W., Breitenbach A., Kaiserling E., Xiao J.X., Kissel T. Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake?. Eur J Pharm Biopharm 2000, 50:147-160.
34. Schipper N.G., Olsson S., Hoogstraate J.A., de Boer A.G., Varum K.M., Artursson P. Chitosans as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement. Pharm Res 1997, 14:923-929.
35. Lehr C.M., Bouwstra J.A., Tukker J.J., Junginger H.E. Intestinal transit of bioadhesive microspheres in an in situ loop in the rat-a comparative study with copolymer and blends on poly(acrylic acid). J Control Release 1990, 13:51-62.
36. Okamoto C.T. Endocytosis and transcytosis. Adv Drug Deliv Rev 1998, 29:215-228.
37. des Rieux A., Fievez V., Garinot M., Scheider Y.-J., Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 2006, 116:1-27.
38. Jani P.U., Halbert G.W., Langridge J., Florence A.T. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol 1990, 42:821-826.
39. O'Hagan D.T. Intestinal translocation of particulates-implications for drug and antigen delivery. Adv Drug Deliv Rev 1990, 5:265-285.
40. Lavelle E.C., Sharif S., Thomas N.W., Holland J., Davis S.S. The importance of gastrointestinal uptake of particles in the design of oral delivery systems. Adv Drug Deliv Rev 1995, 18:5-22.
41. Jani P.U., Florence A.T., McCarthy D.E. Further histological evidence of the gastrointestinal absorption of polystyrene nanospheres in the rat. Int J Pharm 1992, 84:245-252.
42. Desai M.P., Labhasetwar V., Amidon G.L., Levy R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 1996, 13:1838-1845.
43. Desai M.P., Labhasetwar V., Walter E., Levy R.J., Amidon G.L. The mechanism of uptake of biodegradable microparticles in Caco-2 cells is size dependent. Pharm Res 1997, 14:1568-1573.
44. Ankola D.D., Kumar M.N.V.R., Chiellini F., Solaro R. Multiblock copolymers of lactic acid and ethylene glycol containing periodic side-chain carboxyl groups: synthesis, characterization and nanoparticle preparation. Macromolecules 2009, 42:7388-7395.
45. You Z., Cao H., Gao J., Shin P.H., Day B.W., Wang Y. A functionalizable polyester with free hydroxyl groups and tunable physiochemical and biological properties. Biomaterials 2010, 31:129-138.
46. Bala I., Hariharan S., Kumar M.N.V.R. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst 2004, 21:387-422.
47. Shive M.S., Anderson J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997, 28:5-24.
48. Mohamed F., Van der Walle C.F. Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J Pharm Sci 2008, 97:71-87.
49. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 2010, 1:1-18.
50. Bhardwaj V., Ankola D.D., Gupta S.C., Schneider M., Lehr C.-M., Kumar M.N.V.R. PLGA nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat. Pharm Res 2009, 26:2495-2503.
51. Kalaria D.R., Sharma G., Beniwal V., Kumar M.N.V.R. Design of biodegradable nnoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res 2008, 26:492-501.
52. Hariharan S., Bhardwaj V., Bala I., Sitterberg J., Bakowsky U., Kumar M.N.V.R. Design of estradiol loaded PLGA nanoparticulate formulations: a potential oral delivery system for hormone therapy. Pharm Res 2006, 23:184-195.
53. Mittal G., Sahana D.K., Bhardwarj V., Kumar M.N.V.R. Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behaviour in vitro and in vivo. J Control Release 2007, 119:77-85.
54. Sahana D.K., Mittal G., Bhardwaj V., Kumar M.N.V.R. PLGA nanoparticles for oral delivery of hydrophopic drugs: influence of organic solvent on nanoparticle formation and release behaviour in vitro and in vivo using estradiol as a model drug. J Pharm Sci 2008, 97:1530-1542.
55. Mittal G., Kumar M.N.V.R. Impact of polymeric nanoparticles on oral pharmacokinetics: a dose-dependent case study with estradiol. J Pharm Sci 2009, 98:3730-3734.
56. Mittal G., Chandraiah G., Ramarao P., Kumar M.N.V.R. Pharmacodynamic evaluation of oral estradiol nanoparticles in estrogen deficient (ovariectomized) high-fat diet induced hyperlipidemic rat model. Pharm Res 2009, 26:218-223.
57. Italia J.L., Yahya M.M., Singh D., Kumar M.N.V.R. Biodegradable nanoparticles improve oral bioavailability of amphotericin b and show reduced nephrotoxicity compared to intravenous Fungizone®. Pharm Res 2009, 26:1324-1331.
58. Italia J.L., Bhatt D.K., Bhardwaj V., Tikoo K., Kumar M.N.V.R. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral®. J Control Release 2007, 119:197-206.
59. Meena A.K., Ratnam D.V., Godugu C., Ankola D.D., Ramarao P., Kumar M.N.V.R. Oral nanoparticulate Atrovastatin calcium is more efficient and safe in comparison to lipicure in treating hyperlipidemia. Lipids 2008, 43:231-241.
60. Ratnam D.V., Ankola D.D., Bhardwaj V., Sahana D.K., Kumar M.N.V.R. Role of antioxidants in prophylaxis and therapy: a pharmaceutical perspective. J Control Release 2006, 113:189-207.
61. Ankola D.D., Viswanand B., Bhardwaj V., Ramarao P., Kumar M.N.V.R. Development of potent oral nanoparticulate formulation of coenzyme Q 10 for treatment of hypertension: can the simple nutritional supplements be used as first line therapeutic agents for prophylaxis/therapy?. Eur J Pharm Biopharm 2007, 67:361-369.
62. Shaikh J., Ankola D.D., Beniwal V., Singh D., Kumar M.N.V.R. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcuminn administered with piperine as absorption enhancer. Eur J Pharm Sci 2009, 37:223-230.
63. Bala I., Bhardwaj V., Hariharan S., Kharade S.V., Roy N., Kumar M.N.V.R. Sustained release nanoparticulate formulation containing antioxidant-ellagic acid as potential prophylaxix system for oral administration. J Drug Target 2006, 14:27-34.
64. Bala I., Bhardwaj V., Hariharan S., Sitterberg S., Bakowsky U., Kumar M.N.V.R. Design of biodegradable nanoparticles: a novel approach to encapsulating poorly soluble phytochemical ellagic acid. Nanotechnology 2005, 16:2819-2822.
65. Sonaje K., Italia J.L., Sharma G., Bhardwaj V., Tikoo K., Kumar M.N.V.R. Development of biodegradable nanoparticles for oral delivery of ellagic acid and evaluation of their antioxidant efficacy against cyclosporine a-induced nehrotoxicity in rats. Pharm Res 2007, 24:899-908.
66. Italia J.L., Datta P., Ankola D.D., Kumar M.N.V.R. Nanoparticles enhance per oral bioavailability of poorly available molecules: epigallocatechin gallate nanoparticles ameliorates cyclosporine induced nephrotoxicity in rats at three times lower dose than oral solution. J Biomed Nanotechnol 2008, 4:304-312.
67. van Vugt R.M., Rijken P.J., Rietveld A.G., van Vugt A.C., Dijkmans B.A. Antioxidant intervention in rheumatoid arthritis: result of an open pilot study. Clin Rheumatol 2008, 27:771-775.
68. Galli F., Azzi A. Present trends in vitamin E research. Biofactors 2010, 36:33-42.
69. Ratnam D.V., Godugu C., Sonaje K., Viswand B., Bhardwaj V., Ramarao P., et al. A potential therapeutic Strategy for diabetes and its complications in the form of co-encapsulated antioxidant nanoparticles (NanoCAPs) of ellagic acid and coenzyme Q 10: preparation and evaluation in streptozocin induced diabetic rats. J Biomed Nanotechnol 2008, 4:33-43.
70. Ratnam D.V., Godugu C., Meena A.K., Ramarao P., Kumar M.N.V.R. The co-encapsulated antioxidant nanoparticles of ellagic acid and coenzyme Q 10 ameliorates hyperlipidemia in high fat diet fed rats. J Nanosci Nanotechnol 2009, 9:6741-6746.
71. Mora-Huertas C.E., Fessi H., Elaissari A. Polymer-based nanocapusles for drug delivery. Int J Pharm 2010, 385:113-142.
72. Kumar M.N.V.R., Bakowsky U., Lehr C.M. Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials 2004, 25:1771-1777.